Fidia Secures CONSOB Green Light for Share Admission as It Races to Stabilize Finances

Fidia Spa ( (IT:FDA) ) just unveiled an update.

Fidia has obtained authorization from Italy’s securities regulator CONSOB to publish the prospectus for the admission to trading on Euronext Milan of new ordinary shares that will be issued upon conversion of a €5 million convertible bond loan cum warrant reserved for Global Growth Holding Limited and its affiliates, marking a key step in its capital-raising plan following the end of creditor composition proceedings. The company disclosed that its estimated net financial requirement for the 12 months after the prospectus date is about €3 million, which it plans to cover through additional operating cash flows, debt rescheduling and, only as a last resort, proceeds from the new convertible bond; management warned that failure of these measures could exhaust liquidity by April 2026 and jeopardize its going-concern status, even as an updated industrial plan projects sharply higher revenues, a return to positive EBITDA starting in 2025 and a swing to a positive net financial position in 2026, assumptions that hinge on uncontracted future orders and successful debt renegotiations.

The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.11 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.

More about Fidia Spa

Fidia S.p.A. is an Italian industrial group based in Turin and listed on Euronext Milan, specializing in numerical controls and the design, production and marketing of high‑performance integrated milling systems for advanced manufacturing applications worldwide.

Average Trading Volume: 1,089,978

Technical Sentiment Signal: Strong Sell

Current Market Cap: €3.51M

For detailed information about FDA stock, go to TipRanks’ Stock Analysis page.